Changes

==Treatment==

==Treatment==

Anticholinesterase agents inhibit the cholinesterase enzyme breaking down acetycholine resulting in increases level and duration of the neurotransmitter in the synaptic cleft.

Anticholinesterase agents are the most common treament for Myasthenia Gravis. They inhibit the cholinesterase enzyme breaking down acetycholine resulting in increased levels and duration of the neurotransmitter in the synaptic cleft.

Anticholinesterase agents include Pyridostigmine bromide and neostigmine

Anticholinesterase agents include Pyridostigmine bromide and neostigmine.

Animals should be fed from a height and also have their head held in an elevated position for 5 minutes after feeding to avoid aspiration of food and the development of aspiration pneumonia.

Animals should be fed from a height and also have their head held in an elevated position for 5 minutes after feeding to avoid aspiration of food and the development of aspiration pneumonia.

Any accompanying megaoesophagus must also be treated appropriately.

Any accompanying megaoesophagus must also be treated appropriately (antibiotics and oxygen).

Certain drugs including [[Aminoglycosides|aminoglycosides]] and antiarrhythmic drugs can intefere with neuromuscular transmission and should be avoided in myasthenia gravis patients.

Certain drugs including [[Aminoglycosides|aminoglycosides]] and antiarrhythmic drugs can intefere with neuromuscular transmission and should be avoided in myasthenia gravis patients.

==Prognosis==

==Prognosis==